PZRX - PhaseRx, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5886
+0.0376 (+6.8240%)
As of 11:20AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.5510
Open0.5800
Bid0.5800 x 8000
Ask0.5897 x 1900
Day's Range0.5700 - 0.6400
52 Week Range0.5037 - 1.9500
Volume386,300
Avg. Volume1,107,945
Market Cap6.881M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-1.1870
Earnings DateNov 6, 2017 - Nov 10, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • PhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy News
    SmarterAnalyst23 hours ago

    PhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy News

    Monday turned out to be a nightmare for PhaseRx Inc (NASDAQ:PZRX) investors after the biopharmaceutical firm announced that it has filed for Chapter 11 bankruptcy protection. PhaseRx expects to continue to manage and operate its business under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. Contemporaneous with the filing of the Chapter 11 petition, the company is working with Cowen and Company to review financial and strategic alternatives with the goal of maximizing stockholder value.

  • The Wall Street Journalyesterday

    [$$] PhaseRx, a Developer of Liver Drugs, Files for Bankruptcy

    PhaseRx Inc., a developer of drugs to treat life-threatening liver diseases in children, has filed for chapter 11 bankruptcy, about a year after going public with the backing of several venture capital ...

  • PR Newswireyesterday

    PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding

    SEATTLE, Dec. 11, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. PhaseRx intends to continue to manage and operate its business under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The company is working with Cowen and Company to review financial and strategic alternatives with the goal of maximizing stockholder value.

  • SmarterAnalyst14 days ago

    PhaseRx Inc (PZRX) Stock Rallies on Investor Optimism Over Orphan Drug Designation in the European Union

    Shares of PhaseRx Inc (NASDAQ:PZRX) skyrocket over 70% today, after the drug maker announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the Orphan Medicinal Product Application for PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD). To be eligible for orphan medicinal product designation, the Company had to establish medically plausible evidence that PRX-ASL will provide a significant benefit over existing approved therapies in the European Union for the treatment of ASLD.

  • PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency
    PR Newswire14 days ago

    PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency

    SEATTLE, Nov. 28, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD), PhaseRx's second drug candidate to treat a urea cycle disorder.

  • PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update
    PR Newswirelast month

    PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update

    SEATTLE , Nov. 9, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • Does PhaseRx Inc’s (PZRX) Debt Level Pose A Serious Problem?
    Simply Wall St.last month

    Does PhaseRx Inc’s (PZRX) Debt Level Pose A Serious Problem?

    Investors are always looking for growth in small-cap stocks like PhaseRx Inc (NASDAQ:PZRX), with a market cap of USD $8.07M. However, an important fact which most ignore is: how financiallyRead More...

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within Tandem Diabetes Care, CASI Pharmaceuticals, SAExploration, Roka Bioscience, VirnetX, and PhaseRx – Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 02, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tandem ...

  • PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options
    PR Newswire2 months ago

    PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options

    SEATTLE, Oct. 26, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced receipt of a delisting notice from Nasdaq, which informed the company that, absent an appeal, trading in PhaseRx's common stock will be suspended from Nasdaq at the opening of business on November 1, 2017. PhaseRx will appeal the decision to a Nasdaq Hearing Panel, which will stay the suspension of their securities, pending the panel's decision subsequent to the hearing. PhaseRx received notification from the Listing Qualifications Department of the Nasdaq Stock Market on August 22, 2017, indicating that the company no longer complied with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market.

  • ACCESSWIRE2 months ago

    Featured Company News - PhaseRx Announces Cutback in Workforce; Considers Corporate Restructuring

    LONDON, UK / ACCESSWIRE / October 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for PhaseRx, Inc. (NASDAQ: PZRX ), following which we have published ...

  • PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives
    PR Newswire2 months ago

    PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives

    SEATTLE, Oct. 13, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its board of directors has made a determination to conduct a restructuring of operations to reduce short term operating costs and delay the development of its lead product candidate PRX-OTC. The company has not set a timetable for this process. No decision has been made as to whether the company will engage in a transaction or transactions and there can be no assurance that the review of strategic alternatives will result in a transaction, or the terms or timing of any potential transaction that may take place.

  • PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency
    PR Newswire3 months ago

    PhaseRx Receives Orphan Drug Designation from FDA for PRX-ASL for the Treatment of Argininosuccinate Lyase Deficiency

    SEATTLE, Sept. 20, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its second drug development candidate, PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD), has received orphan drug designation by the U.S. Food and Drug Administration (FDA). ASLD is a rare liver disorder caused by an inherited single-gene deficiency that results in hyperammonemia (elevated ammonia in the blood), and can lead to irreversible neurological impairment, coma and death.

  • PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update
    PR Newswire4 months ago

    PhaseRx Reports Second Quarter 2017 Financial Results and Provides Corporate Update

    SEATTLE , Aug. 10, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update
    PR Newswire7 months ago

    PhaseRx Reports First Quarter 2017 Financial Results and Provides Corporate Update

    SEATTLE, May 12, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting
    PR Newswire7 months ago

    PhaseRx to Present Data at the American Society of Gene & Cell Therapy 20th Annual Meeting

    SEATTLE, May 3, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a poster ...

  • Accesswire7 months ago

    Today's Research Reports on Stocks to Watch: Cempra and PhaseRx

    NEW YORK, NY / ACCESSWIRE / May 1, 2017 / U.S. markets fell Friday after data showed the U.S. economy grew at a slower than expected pace in the first quarter. The Dow Jones Industrial Average fell 0.19 ...

  • PhaseRx to Present Data at the TIDES Conference
    PR Newswire8 months ago

    PhaseRx to Present Data at the TIDES Conference

    SEATTLE, April 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a ...

  • PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency
    PR Newswire8 months ago

    PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-OTC from European Medicines Agency

    SEATTLE, April 25, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for PRX-OTC for the treatment of ornithine transcarbamylase deficiency (OTCD). OTCD is a rare genetic disorder characterized by a complete or partial lack of the enzyme ornithine transcarbamylase, an essential urea cycle enzyme that facilitates the break down and removal of ammonia from the body.

  • PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
    PR Newswire9 months ago

    PhaseRx Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update

    SEATTLE, March 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • PR Newswire9 months ago

    PhaseRx to Present at Upcoming Investor Conferences

    SEATTLE , Feb. 27, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced ...

  • PR Newswire10 months ago

    PhaseRx to Present Data for PRX-OTC at the 13th Annual WORLDSymposium™ 2017

    SEATTLE, Feb. 8, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced a poster ...

  • PR Newswire11 months ago

    PhaseRx to Present at Biotech Showcase 2017

    SEATTLE, Jan. 4, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that ...